The Prognostic Value and Potential Immune Mechanisms of lncRNAs Related to Immunogenic Cell Death in Papillary Thyroid Carcinoma

References

• Sung H, Ferlay J, Siegel RL., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–653. doi:10.1038/nrendo.2016.110
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783–2795.
   PubMed Web of Science ®Google Scholar
• Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–1348. doi:10.1001/jama.2017.2719
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/s41590-022-01132-2
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541. doi:10.1038/s41418-017-0012-4
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1158/2326-6066.CIR-19-0616
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487–500.
   PubMed Web of Science ®Google Scholar
• Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–108.
   PubMed Web of Science ®Google Scholar
• Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci. 2019;44:33–52. doi:10.1016/j.tibs.2018.09.012
   PubMed Web of Science ®Google Scholar
• Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21:102–117. doi:10.1038/s41576-019-0184-5
   PubMed Web of Science ®Google Scholar
• Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21:22–36. doi:10.1038/s41568-020-00306-0
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang T, Zhou W, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11:1000. doi:10.1038/s41467-020-14802-2
   PubMed Web of Science ®Google Scholar
• Li G, Kryczek I, Nam J, et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021;23:526–537. doi:10.1038/s41556-021-00672-3
   PubMed Web of Science ®Google Scholar
• Munteanu MC, Sethuraman SN, Singh MP, Malayer J, Ranjan A. LncRNA FENDRR expression correlates with tumor immunogenicity. Genes. 2021;12:897. doi:10.3390/genes12060897
   PubMed Web of Science ®Google Scholar
• Hu Q, Ye Y, Chan L-C, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20:835–851. doi:10.1038/s41590-019-0400-7
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–416.e11. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–1120. doi:10.1038/ng.2764
   PubMed Web of Science ®Google Scholar
• Lee CM, Barber GP, Casper J, et al. UCSC genome browser enters 20th year. Nucleic Acids Res. 2020;48:D756–D761. doi:10.1093/nar/gkz1012
   PubMed Web of Science ®Google Scholar
• Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2015;5:e1069938. doi:10.1080/2162402X.2015.1069938
   PubMed Web of Science ®Google Scholar
• Bezu L, Sauvat A, Humeau J, et al. eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25:1375–1393. doi:10.1038/s41418-017-0044-9
   PubMed Web of Science ®Google Scholar
• Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904. doi:10.1084/jem.20160801
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011;208:491–503. doi:10.1084/jem.20100269
   PubMed Web of Science ®Google Scholar
• Mónaco A, Chilibroste S, Yim L, Chabalgoity JA, Moreno M. Inflammasome activation, NLRP3 engagement and macrophage recruitment to tumor microenvironment are all required for Salmonella antitumor effect. Cancer Immunol Immunother. 2022;71:2141–2150. doi:10.1007/s00262-022-03148-x
   PubMed Web of Science ®Google Scholar
• Lau TS, Chan LKY, Man GCW, et al. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. Cancer Immunol Res. 2020;8:1099–1111. doi:10.1158/2326-6066.CIR-19-0616
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
   PubMed Web of Science ®Google Scholar
• Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings Bioinf. 2021;22(6):bbab260.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Xie Z, Li X, He Y, et al. Immune cell confrontation in the papillary thyroid carcinoma microenvironment. Front Endocrinol. 2020;11:570604. doi:10.3389/fendo.2020.570604
   PubMed Web of Science ®Google Scholar
• Dong X, Yang Q, Gu J, et al. Identification and validation of L antigen family member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. Int Immunopharmacol. 2021;90:107267. doi:10.1016/j.intimp.2020.107267
   PubMed Web of Science ®Google Scholar
• Minute L, Teijeira A, Sanchez-Paulete AR, et al. Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer. 2020;8:e000325. doi:10.1136/jitc-2019-000325
   PubMed Web of Science ®Google Scholar
• Hayashi K, Nikolos F, Lee YC, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020;11:6299. doi:10.1038/s41467-020-19970-9
   PubMed Web of Science ®Google Scholar
• Jiang LH, Yin KX, Wen QL, Chen C, Ge MH, Tan Z. Predictive risk-scoring model for central lymph node metastasis and predictors of recurrence in papillary thyroid carcinoma. Sci Rep. 2020;10(1):710. doi:10.1038/s41598-019-55991-1
   PubMed Web of Science ®Google Scholar
• Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol. 2015;15:683–691. doi:10.1038/nri3904
   PubMed Web of Science ®Google Scholar
• Yang G, Lu S-B, Li C, et al. Type I macrophage activator photosensitizer against hypoxic tumors. Chem Sci. 2021;12:14773–14780. doi:10.1039/d1sc04124j
   PubMed Web of Science ®Google Scholar
• Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun. 2014;6:716–726. doi:10.1159/000364945
   PubMed Web of Science ®Google Scholar
• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356–371. doi:10.1038/s41571-019-0175-7
   PubMed Web of Science ®Google Scholar
• Huang F-Y, Lei J, Sun Y, et al. Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes. Oncoimmunology. 2018;7:e1446720. doi:10.1080/2162402X.2018.1446720
   PubMed Web of Science ®Google Scholar
• Wang H, Tang Y, Fang Y, et al. Reprogramming Tumor Immune Microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett. 2019;19:2935–2944. doi:10.1021/acs.nanolett.9b00021
   PubMed Web of Science ®Google Scholar
• Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5–16. doi:10.1038/s41422-020-0383-9
   PubMed Web of Science ®Google Scholar
• Han A, Li C, Zahed T, et al. Calreticulin is a critical cell survival factor in malignant neoplasms. PLoS Biol. 2019;17:e3000402.
   PubMed Web of Science ®Google Scholar
• Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, et al. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. J Immunother Cancer. 2020;8:e000698. doi:10.1136/jitc-2020-000698
   PubMed Web of Science ®Google Scholar
• Mould RC, van Vloten JP, AuYeung AWK, Karimi K, Bridle BW. Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission. Endocr Relat Cancer. 2017;24:T311–T329. doi:10.1530/ERC-17-0316
   PubMed Web of Science ®Google Scholar
• Liotti F, Kumar N, Prevete N, et al. PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. J Exp Clin Cancer Res. 2021;40:22. doi:10.1186/s13046-020-01818-1
   PubMed Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207. doi:10.1038/nrendo.2016.205
   PubMed Web of Science ®Google Scholar
• Yu K, Mei Y, Wang Z, Liu B, Deng M. LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma. J Med Virol. 2022;94:2702–2713. doi:10.1002/jmv.27578
   PubMed Web of Science ®Google Scholar